Fosamprenavir calcium plus ritonavir for HIV infection

References

• Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA296(7), 827–843 (2006).
   PubMed Web of Science ®Google Scholar
• DHHS. The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 10 (2006).
   Google Scholar
• Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med.7(8), 487–503 (2006).
   PubMed Web of Science ®Google Scholar
• Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet.45(2), 137–168 (2006).
   PubMed Web of Science ®Google Scholar
• Package insert. Lexiva® (fosamprenavir).
   Google Scholar
• Hester EK, Chandler HV, Sims KM. Fosamprenavir: drug development for adherence. Ann. Pharmacother.40(7–8), 1301–1310 (2006).
   PubMedGoogle Scholar
• Wood R, Arasteh K, Stellbrink HJ et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother.48(1), 116–123 (2004).
   PubMed Web of Science ®Google Scholar
• Flexner C. HIV-protease inhibitors. N. Engl. J. Med.338(18), 1281–1292 (1998).
   PubMed Web of Science ®Google Scholar
• Schurmann D, Elston R, Xu F, Kleinkauf N, Wunsche T, Suttorp N. Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. AIDS20(1), 138–140 (2006).
   PubMedGoogle Scholar
• Maguire M, Shortino D, Klein A et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother.46(3), 731–738 (2002).
   PubMedGoogle Scholar
• Pellegrin I, Coureau G, Neau D et al. Fosamprenavir/ritonavir based HAART in antiretroviral experienced patients (Zephir study). Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, H-1059 (2005).
   Google Scholar
• Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv. Exp. Med. Biol.436, 75–83 (1998).
   PubMedGoogle Scholar
• MacManus S, Yates PJ, White S et al. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. MA, USA, 598 (2003).
   Google Scholar
• MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS18(4), 651–655 (2004).
   PubMed Web of Science ®Google Scholar
• Holmes H, Bell T, Barnett B, Arduino R. Emerging resistance mutations in once-daily ritonavir-boosted protease inhibitor-containing antiretroviral regimens. Proceedings of the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Ontario, Canada, 973 (2006).
   Google Scholar
• Masquelier B, Assoumou K, Descamps D et al. Genotypic determinants of the virological response to fosamprenavir/ritonavir in protease inhibitors experienced patients. Antivir. Ther.11(S101) (2006).
   Google Scholar
• Pellegrin I, Breilh D, Coureau G et al. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir/ritonavir-based regimens in antiretroviral-experienced patients (Zephir Study). Antimicrob. Agents Chemother.51(4), 1473–1480 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Korn K, Moschik B, Paatz C, Uberla K, Walter H. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob. Agents Chemother.44(11), 3213–3216 (2000).
   PubMed Web of Science ®Google Scholar
• Elston RC, Yates P, Tisdale M, Richards N, White S, DeJesus E. GW433908 (908)/ritonavir: 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, MoOrB1055 (2004).
   Google Scholar
• Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol.74(9), 4414–4419 (2000).
   PubMed Web of Science ®Google Scholar
• Lam E, Parkin NT. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clin. Infect. Dis.37(9), 1273–1274 (2003).
   PubMedGoogle Scholar
• Zachary KC, Hanna GJ, D’Aquila RT. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.Clin. Infect. Dis.33(12), 2075–2077 (2001).
   PubMed Web of Science ®Google Scholar
• Spaltenstein A, Baker C, Gray-Nunez Y et al. Highly polar, watersoluble prodrugs of amprenavir: a new approach toward a more compact dosing regimen. Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections. CA, USA, 505 (2000).
   Google Scholar
• Baker CT, Chamrvedi PR, Hale MR et al. Discovery of VX175/GW433908, a novel, water soluble prodrug of amprenavir. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 916 (1999).
   Google Scholar
• Furfine ES, Baker CT, Hale MR et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother.48(3), 791–798 (2004).
   PubMed Web of Science ®Google Scholar
• Polli JW, Jarrett JL, Studenberg SD et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res.16(8), 1206–1212 (1999).
   PubMed Web of Science ®Google Scholar
• Arvieux C, Tribut O. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs65(5), 633–659 (2005).
   PubMedGoogle Scholar
• Chappuy H, Treluyer JM, Rey E et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am. J. Obstet. Gynecol.191(2), 558–562 (2004).
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr, Smeaton LM, Fiscus SA et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J. Infect. Dis.181(5), 1622–1628 (2000).
   PubMedGoogle Scholar
• Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci.87(7), 803–807 (1998).
   PubMed Web of Science ®Google Scholar
• Pfister M, Labbe L, Lu JF et al. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther.72(2), 133–141 (2002).
   PubMed Web of Science ®Google Scholar
• Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother.45(1), 30–37 (2001).
   PubMed Web of Science ®Google Scholar
• Sadler BM, Chittick GE, Polk RE et al. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. J. Clin. Pharmacol.41(4), 386–396 (2001).
   PubMed Web of Science ®Google Scholar
• Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother.43(7), 1686–1692 (1999).
   PubMed Web of Science ®Google Scholar
• Polk RE, Crouch MA, Israel DS et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy19(12), 1378–1384 (1999).
   PubMed Web of Science ®Google Scholar
• Polk RE, Brophy DF, Israel DS et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob. Agents Chemother.45(2), 502–508 (2001).
   PubMed Web of Science ®Google Scholar
• Wire MB, Baker KL, Moore KHP et al. The pharmacokinetic interaction of GW433908 (908) with atorvastatin and 908/ritonavir with atorvastatin (APV10013). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, A-1622 (2003).
   Google Scholar
• Ford SL, Wire MB, Lou Y, Baker KL, Stein DS. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob. Agents Chemother.49(1), 467–469 (2005).
   PubMed Web of Science ®Google Scholar
• DeJesus E, Piliero PJ, Summers K et al. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother.50(9), 3157–3159 (2006).
   PubMedGoogle Scholar
• Falloon J, Piscitelli S, Vogel S et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis.30(2), 313–318 (2000).
   PubMed Web of Science ®Google Scholar
• Wire MB, Baker KL, Jones LS et al. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob. Agents Chemother.50(4), 1578–1580 (2006).
   PubMedGoogle Scholar
• Ruane PJ, Luber AD, Wire MB et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob. Agents Chemother.51(2), 560–565 (2007).
   PubMed Web of Science ®Google Scholar
• Breilh D, Pellegrin I, Couraud G et al. Switch to fosamprenavir/ritonavir based HAART in experienced patients with virologic failure on HAART zephir study: impact of pharmacokinetics on response at M3. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, H-1903 (2005).
   Google Scholar
• Clay PG, Anderson PL, Smith PF, Lein D, Glaros AG. Pharmacokinetics of once-daily fosamprenavir 1400 mg plus atazanavir 400 mg without ritonavir in HIV negative subjects. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. CO, USA, L-134 (2006).
   Google Scholar
• Khanlou H, Bhatti L, Farthing C. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients. J. Acquir. Immune Defic. Syndr.41(1), 124–125 (2006).
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos.27(2), 180–187 (1999).
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti Infect. Ther.3(4), 467–487 (2005).
   PubMedGoogle Scholar
• Brophy DF, Israel DS, Pastor A et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob. Agents Chemother.44(4), 978–984 (2000).
   PubMed Web of Science ®Google Scholar
• Shelton MJ, Ford SL, Borland J et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J. Acquir. Immune Defic. Syndr.42(1), 61–67 (2006).
   PubMed Web of Science ®Google Scholar
• Bart PA, Rizzardi PG, Gallant S et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther. Drug Monit.23(5), 553–555 (2001).
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Cocchi S, Codeluppi M et al. Pharmacokinetic interaction between amprenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant. Proc.38(4), 1138–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad, II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis.5(12), 775–785 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36(5), 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Mikus G, Schowel V, Drzewinska M et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther.80(2), 126–135 (2006).
   PubMed Web of Science ®Google Scholar
• Pellegrin I, Coureau G, Dupon M et al. Clinically relevant interpretation of genotype and pharmacokinetics parameters for resistance to fosamprenavir/ritonavir-based regimens in ART-experienced patients: Zephir study. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. CO, USA (2006).
   Google Scholar
• Kurowski M, Walli R, Breske A et al. Coadministration of tenofovir 300 mg QD with fosamprenavir/ritonavir 1400/100 mg QD or 1400/200 mg QD does not affect amprenavir pharmacokinetics. Proceedings of the 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Quebec, Canada, 10 (2005).
   Google Scholar
• Hicks C, DeJesus E, Sloan L et al. Efficacy and safety of once-daily boosted fosamprenavir/ritonavir with abacavir/lamivudine fixed dose combination in antiretroviral naive HIV-1 infected patients: 24-week results from COL100758. Proceedings of the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, P2 (2006).
   Google Scholar
• Peytavin G, Marcelin A, Rouault A et al. Therapeutic drug monitoring of boosted tipranavir with and without combination to lopinavir or fosamprenavir. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. CO, USA (2006).
   Google Scholar
• Hammer SM, Vaida F, Bennett KK et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA288(2), 169–180 (2002).
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Tierney C, Downey GF et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS19(2), 145–152 (2005).
   PubMed Web of Science ®Google Scholar
• Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit.28(3), 468–473 (2006).
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Lamotte C, Delaugerre C et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir–amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother.47(2), 594–600 (2003).
   PubMed Web of Science ®Google Scholar
• Gathe JC Jr, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS18(11), 1529–1537 (2004).
   PubMed Web of Science ®Google Scholar
• DeJesus E, LaMarca A, Sension M et al. The CONTEXT study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. MA, USA, 178 (2003).
   Google Scholar
• Rodriguez-French A, Boghossian J, Gray GE et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr.35(1), 22–32 (2004).
   PubMed Web of Science ®Google Scholar
• Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir–ritonavir, each in combination with abacavir–lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet368(9534), 476–482 (2006).
   PubMed Web of Science ®Google Scholar
• Smith K, Weinberg W, DeJesus E et al. Efficacy and safety of once-daily boosted fosamprenavir or atazanavir with tenofovir/emtricitabine in antiretroviral-naïve HIV-1 infected patients: 24-week results from COL103953 (ALERT). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, H-1670a (2006).
   Google Scholar
• Gathe JC Jr, Wood R, Sanne I et al. Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin. Ther.28(5), 745–754 (2006).
   PubMed Web of Science ®Google Scholar
• Yeni P, Eron J, Clotet B et al. The KLEAN Study: fosamprenavir–ritonavir twice daily versus lopinavir–ritonavir twice daily, each in combination with abacavir–lamivudine once daily in antiretroviral naïve subjects. 48 week analysis demonstrates rare resistance and non-inferiority. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, H-1056 (2006).
   Google Scholar
• Cunningham C, Freedman A, Read S et al. Safety and antiviral activity of fosamprenavir-containing regmens in HIV-infected 2- to 18-year-old pediatric subjects (interim data, study APV29005). Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections. CA, USA, 718 (2007).
   Google Scholar
• Chadwick E, Borkowsky W, Fortuny C et al. Safety and antiviral activity of fosamprenavir/ritonavir once daily regimens in HIV-infected pediatric subjects ages 2 to 18 years (48-week interim data, study APV20003). Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections. CA, USA, 719 (2007).
   Google Scholar
• Torres HA, Barnett B, Arduino RC. Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency. Clin. Infect. Dis.44, 887–888 (2007).
   PubMedGoogle Scholar
• Eng R, Slim J, Fallon J et al. Protease inhibitor regimens in clinical practice: durability, tolerability and CD4 cell recovery rates. Proceedings of the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Ontario, Canada, 955 (2006).
   Google Scholar
• Ruane P, Wire M, Shelton M, Lou Y, Lancaster C, Pappa K. Plasma amprenavir pharmacokinetics and safety following co-administration of fosamprenavir with a reduced ritonavir dose once daily (COL10053). Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
   Google Scholar